By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.




CEO: John F. Milligan, PhD

Chief Scientific Officer: Norbert W. Bischofberger, PhD

CFO: Robin L. Washington

COO: Kevin Young


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD

Company News
European CHMP Adopts Positive Opinion For Gilead (GILD)’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes 6/23/2017 6:36:01 AM
Is Gilead (GILD) On The Verge Of A Powerful Rally? 6/22/2017 6:08:28 AM
Why This Tiny Massachusetts Biotech Could be a New M&A Target for Drug Giants Like Gilead (GILD) and Celgene (CELG) 6/16/2017 5:57:26 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Gilead (GILD), Sanofi (SNY) Reportedly Bidding on This $10 Billion Massachusetts Biotech 6/13/2017 5:38:27 AM
Gilead (GILD) Submits New Drug Application To U.S. FDA For Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For HIV Treatment 6/12/2017 12:14:07 PM
The Single Best Hep C Drug Stock to Buy in 2017—Hint, It's Not Gilead (GILD) 6/9/2017 6:12:25 AM
GlaxoSmithKline (GSK) Quietly Paid $130 Million for HIV Priority Voucher to Beat Gilead (GILD) to the Finish Line 6/2/2017 5:56:31 AM
A Look at Gilead (GILD)'s Possible New Drug Strategy 5/31/2017 6:13:24 AM
Gilead (GILD)’s Investigational Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For The Treatment Of HIV-1 Meets Primary Endpoint In Four Phase III Studies 5/30/2017 8:57:54 AM